$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

$tnxp Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000199937124014569 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$2.822M	$3.989M
YoY Change		-29.26%
Cost Of Revenue		$1.555M	$2.374M
YoY Change		-34.5%
Gross Profit		$1.267M	$1.615M
YoY Change		-21.55%
Gross Profit Margin		44.9%	40.49%
Selling, General & Admin		$7.707M	$8.712M
YoY Change		-11.54%	17.89%
% of Gross Profit		608.29%	539.44%
Research & Development		$9.114M	$21.05M
YoY Change		-56.7%	-5.18%
% of Gross Profit		719.34%	1303.41%
Depreciation & Amortization		$510.0K	$1.220M
YoY Change		-58.2%	384.13%
% of Gross Profit		40.25%	75.54%
Operating Expenses		$16.82M	$29.76M
YoY Change		-43.48%	34.06%
Operating Profit		-$15.55M	-$28.15M
YoY Change		-44.74%	-4.88%
Interest Expense			$170.0K
YoY Change			-72.13%
% of Operating Profit
Other Income/Expense, Net		-$327.0K	$172.0K
YoY Change		-290.12%
Pretax Income		-$14.21M	-$27.98M
YoY Change		-49.2%	-3.45%
Income Tax
% Of Pretax Income
Net Earnings		-$14.21M	-$27.98M
YoY Change		-49.19%	-3.47%
Net Earnings / Revenue		-503.65%	-701.3%
Basic Earnings Per Share		-$0.23	-$1.83
Diluted Earnings Per Share		-$0.23	-$1.83
COMMON SHARES
Basic Shares Outstanding	186.9M shares	22.00M shares	17.76M shares
Diluted Shares Outstanding		62.12M shares	15.33M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.23M	$6.900M
YoY Change	309.17%	-95.07%
Cash & Equivalents	$28.23M	$6.914M
Short-Term Investments
Other Short-Term Assets	$2.125M	$9.500M
YoY Change	-77.63%	-14.88%
Inventory	$7.931M	$13.32M
Prepaid Expenses
Receivables	$4.013M	$1.600M
Other Receivables	$2.658M	$0.00
Total Short-Term Assets	$50.54M	$31.34M
YoY Change	61.29%	-79.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.75M	$94.87M
YoY Change	-54.94%	5.05%
Goodwill		$965.0K
YoY Change
Intangibles	$120.0K	$9.982M
YoY Change	-98.8%
Long-Term Investments
YoY Change
Other Assets	$951.0K	$1.051M
YoY Change	-9.51%	191.94%
Total Long-Term Assets	$44.45M	$107.9M
YoY Change	-58.83%	17.96%
TOTAL ASSETS
Total Short-Term Assets	$50.54M	$31.34M
Total Long-Term Assets	$44.45M	$107.9M
Total Assets	$94.99M	$139.3M
YoY Change	-31.8%	-42.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.935M	$7.799M
YoY Change	-49.54%	71.18%
Accrued Expenses	$8.426M	$9.900M
YoY Change	-14.89%	12.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.820M
YoY Change
Total Short-Term Liabilities	$15.18M	$17.73M
YoY Change	-14.39%	32.93%
LONG-TERM LIABILITIES
Long-Term Debt	$5.172M	$0.00
YoY Change
Other Long-Term Liabilities	$425.0K	$700.0K
YoY Change	-39.29%	83.25%
Total Long-Term Liabilities	$5.172M	$700.0K
YoY Change	638.86%	83.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.18M	$17.73M
Total Long-Term Liabilities	$5.172M	$700.0K
Total Liabilities	$20.78M	$18.45M
YoY Change	12.62%	34.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$708.6M	-$573.3M
YoY Change	23.59%	30.79%
Common Stock	$783.0M	$694.4M
YoY Change	12.77%	4.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.21M	$120.8M
YoY Change
Total Liabilities & Shareholders Equity	$94.99M	$139.3M
YoY Change	-31.8%	-42.6%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$14.21M	-$27.98M
YoY Change	-49.19%	-3.47%
Depreciation, Depletion And Amortization	$510.0K	$1.220M
YoY Change	-58.2%	384.13%
Cash From Operating Activities	-$18.80M	-$23.38M
YoY Change	-19.59%	-0.66%
INVESTING ACTIVITIES
Capital Expenditures	$9.000K	$1.820M
YoY Change	-99.51%	-120.63%
Acquisitions
YoY Change
Other Investing Activities		$990.0K
YoY Change
Cash From Investing Activities	-$9.000K	-$820.0K
YoY Change	-98.9%	-90.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	42.91M	6.270M
YoY Change	584.29%	-235.57%
NET CHANGE
Cash From Operating Activities	-18.80M	-23.38M
Cash From Investing Activities	-9.000K	-820.0K
Cash From Financing Activities	42.91M	6.270M
Net Change In Cash	24.10M	-17.93M
YoY Change	-234.38%	-51.51%
FREE CASH FLOW
Cash From Operating Activities	-$18.80M	-$23.38M
Capital Expenditures	$9.000K	$1.820M
Free Cash Flow	-$18.81M	-$25.20M
YoY Change	-25.36%	71.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Address Address Line1 EntityAddressAddressLine1	26 Main Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chatham
	dei	Entity Central Index Key EntityCentralIndexKey	0001430306
	dei	City Area Code CityAreaCode	(862)
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	TNXP
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1434750
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07928
	dei	Local Phone Number LocalPhoneNumber	799-9155
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	186894225	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28233000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24948000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36019
CY2024Q3	us-gaap	Inventory Net InventoryNet	7931000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	13639000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10366000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9181000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	50543000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	47768000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42747000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94028000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9743000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	965000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	824000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	951000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1129000	usd
CY2024Q3	us-gaap	Assets Assets	94989000	usd
CY2023Q4	us-gaap	Assets Assets	154457000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3935000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3782000	usd
CY2024Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	8151000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2820000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2350000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	275000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15181000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5172000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6561000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	425000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	632000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	20778000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	706412000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-600658000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-232000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	105525000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	154457000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3989000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3989000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	2374000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2374000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21050000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31675000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69535000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24519000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	32136000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	121733000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	95040000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-28147000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-114221000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-91051000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-38.63
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-38.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.66
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62122283	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62122283	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	724190	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	724190	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23136172	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23136172	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2024Q3	us-gaap	Goodwill Goodwill		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2024Q1	tnxp	Issuance Of Common Stock Upon Exercise Of Prefunded Warrants IssuanceOfCommonStockUponExerciseOfPrefundedWarrants		usd
CY2024Q2	tnxp	Issuance Of Common Stock Upon Exercise Of Prefunded Warrants IssuanceOfCommonStockUponExerciseOfPrefundedWarrants		usd
CY2024Q3	tnxp	Issuance Of Common Stock Upon Exercise Of Prefunded Warrants IssuanceOfCommonStockUponExerciseOfPrefundedWarrants		usd
CY2023Q3	tnxp	Issuance Of Common Stock Upon Exercise Of Prefunded Warrants Under Financing IssuanceOfCommonStockUponExerciseOfPrefundedWarrantsUnderFinancing		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	tnxp	At The Market Agreement Receivable AtTheMarketAgreementReceivable		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-708586000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28233000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	476000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	238000	usd
	us-gaap	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2024#CostsAndExpenses
	us-gaap	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	1668000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2018000	usd
CY2023Q4	tnxp	At The Market Receivable AtTheMarketReceivable		usd
CY2023Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent		usd
CY2024Q3	us-gaap	Goodwill Goodwill		usd
CY2023Q4	tnxp	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment		usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	628000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	700000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	425000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	275000	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Registrant Name EntityRegistrantName	TONIX PHARMACEUTICALS HOLDING CORP.
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4013000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	628000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	12482000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	270000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18884000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	48932000	usd
CY2024Q3	tnxp	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2023Q4	tnxp	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	155631049	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155631049	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2077088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2077088	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2074	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	156000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	782891000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-708586000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-250000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	74211000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94989000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2822000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7512000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	1555000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6582000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9114000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7707000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8712000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23131000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	58957000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	18376000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15554000	usd
CY2024Q3	us-gaap	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	1668000	usd
CY2023Q3	us-gaap	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	0	usd
	us-gaap	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	1668000	usd
	us-gaap	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6150000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-327000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	172000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1525000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1715000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14213000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27975000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107928000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89336000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-143.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-143.47
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	622684	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	622684	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14213000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-27975000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-107928000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89336000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-18000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14220000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27983000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107946000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89389000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	105525000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	15850000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	23000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1692000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-14939000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	108143000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1704000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10730000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-9977000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10832000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1154000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-78776000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	42103000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	557000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3484000	usd
CY2024Q3	tnxp	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs At The Market AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsAtTheMarket	1681000	usd
CY2024Q3	tnxp	Stock Issued During Period Value New Issues At The Market StockIssuedDuringPeriodValueNewIssuesAtTheMarket	41802000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1038000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14213000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	74211000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	207182000	usd
CY2023Q1	tnxp	Stock Repurchased During Period Transactional Expenses StockRepurchasedDuringPeriodTransactionalExpenses	334000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13965000	usd
CY2023Q1	tnxp	Stock Issued During Period Value New Issues1 StockIssuedDuringPeriodValueNewIssues1	441000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	101000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1995000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	29000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2794000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-44000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-33005000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	165427000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	36000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1029000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2364000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-28356000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	140463000	usd
CY2023Q3	tnxp	Issuance Of Common Stock Under Financing Transactional Expenses IssuanceOfCommonStockUnderFinancingTransactionalExpenses	726000	usd
CY2023Q3	tnxp	Stock Issued During Period Under Financing StockIssuedDuringPeriodUnderFinancing	6274000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6274000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2079000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-27975000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	120833000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-107928000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89336000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2925000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3030000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	58957000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	196000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6150000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2018000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	640000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3884000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7237000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4982000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1562000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3691000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-670000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3334000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	346000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	446000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	24000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-358000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2640000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46295000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-79663000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	22174000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	992000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7457000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-117000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28639000	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	3000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13965000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	27000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	29000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1645000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3942000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	863000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54336000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9739000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49718000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4197000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-20000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-55000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3286000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-112554000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25850000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120470000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29136000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7916000	usd
	us-gaap	Interest Paid Net InterestPaidNet	954000	usd
	tnxp	At The Market Agreement Receivable AtTheMarketAgreementReceivable	1680000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	275000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_z3XxJo647XH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_826_zq0OLvz0OEfh">BUSINESS</span></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tonix Pharmaceuticals Holding Corp. (“Tonix” or the “Company”), through its wholly owned subsidiary Tonix Pharmaceuticals, Inc. (“Tonix Sub”), is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tonix’s priority is to advance its TNX-102 SL product candidate for the management of fibromyalgia, for which a New Drug Application (“NDA”) was submitted to the U.S. Food and Drug Administration (“FDA”) based on two statistically significant Phase 3 studies. The FDA granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in the third quarter 2024. The Company expects an FDA decision on the acceptance of the NDA for review and PDUFA date in December and if accepted, a decision on NDA approval in 2025. Fibromyalgia is a common chronic pain condition that affects mostly women. Fibromyalgia is now recognized as the prototypic nociplastic pain syndrome. TNX-102 SL is a non-opioid, centrally acting analgesic developed for long-term use in fibromyalgia. If approved, TNX-102 SL would be the first new drug therapy for fibromyalgia in more than 15 years. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated Investigational New Drug application (“IND”) at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (“DoD”). We expect to initiate enrollment in the OASIS study in the fourth quarter. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic drug candidate in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute of Drug Abuse. Tonix’s immunology development portfolio includes TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) in Phase 1 development for the prevention of allograft rejection and for the treatment of autoimmune diseases. TNX-1700 is a fusion protein of TFF2 and albumin and is in the pre-IND stage of development to treat gastric and pancreatic cancer. Tonix also has pre-clinical product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including TNX-801, a potential vaccine to prevent mpox and smallpox. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (“DTRA”) for up to $<span id="xdx_90C_ecustom--DevelopmentContract_iI_pn6n6_c20240930__srt--ProductOrServiceAxis__custom--TNX4200Member_zNT0cAvl2Ls">34</span> million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace<sup>® </sup>SymTouch<sup>®</sup> (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Sub, Krele LLC, Tonix Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., Jenner Institute LLC, Tonix R&D Center LLC, Tonix Pharma Holdings Limited and Tonix Pharma Limited (collectively, the “Company” or “Tonix”). All intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses from operations and negative cash flows from operating activities. At September 30, 2024, the Company had working capital of approximately $<span id="xdx_906_ecustom--WorkingCapital_iI_pn5n6_c20240930_z2NHDzpXHB0i" title="Working capital">35.4</span> million. At September 30, 2024, the Company had an accumulated deficit of approximately $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20240930_zPFjPyoFOrl9" title="Accumulated deficit::XDX::-708586"><span style="-sec-ix-hidden: xdx2ixbrl0755">708.6</span></span> million. The Company held unrestricted cash and cash equivalents of approximately $<span id="xdx_90D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dxL_c20240930_zWBshHYt9tD" title="Cash and cash equivalents::XDX::28233"><span style="-sec-ix-hidden: xdx2ixbrl0757">28.2</span></span> million as of September 30, 2024. During the fourth quarter of 2023, the Company engaged CBRE, an international real estate brokerage firm, to potentially find a strategic partner for, or buyer of, its Advanced Development Center in North Dartmouth, Massachusetts (“ADC”), to align with the Company’s current business objectives and priorities. As of September 30, 2024, the Company does not have a commitment in place to sell the ADC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that its cash resources at September 30, 2024 and the net proceeds of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20241001__20241112__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmYjpVsNVRRg" title="Net proceeds">5.1</span> million that it raised from an equity offering in the fourth quarter of 2024 (See Note 19), will not meet its operating and capital expenditure requirements through the first quarter of 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company continues to face significant challenges and uncertainties and must obtain additional funding through public and private financing and collaborative arrangements with strategic partners to increase the funds available to fund operations. However, the Company may not be able to raise capital on terms acceptable to the Company, or at all. Without additional funds, it may be forced to delay, scale back or eliminate some or all of its research and development activities or other operations, and potentially delay product development in an effort to maintain sufficient funds to continue operations. If any of these events occurs, the Company’s ability to achieve development and commercialization goals will be adversely affected and the Company may be forced to cease operations. Moreover, the Company may default under the terms of its existing indebtedness. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </span></p>
CY2024Q3	tnxp	Working Capital WorkingCapital	35400000	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-32
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zqnp0rcq3Azb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z1EQLkBiUJ42">Risks and uncertainties</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s primary efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company now has commercial products available for sale, and generates revenue from the sale of its Zembrace SymTouch and Tosymra products, with no assurance that the Company will be able to generate sufficient cash flow to fund operations from its commercial products or products in development if and when approved. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zT47y80sFgC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zkZ5omeDiBC4">Use of estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include, but are not limited to, impairments, provisions for product returns, coupons, rebates, chargebacks, discounts, allowances, inventory realization, the assumptions used in the fair value of stock-based compensation and other equity instruments, the percent of completion of research and development contracts, fair value estimates for assets acquired in business combinations, and assessment of useful lives of acquired intangible assets. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	24000	usd
CY2023Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3700000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28233000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6914000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	903000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	1002000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29136000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7916000	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1000000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2800000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	48800000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	9200000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	965000	usd
	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	30 to 90 days
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	1100000	usd
CY2024Q3	us-gaap	Government Assistance Amount Cumulative Current GovernmentAssistanceAmountCumulativeCurrent	300000	usd
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	2300000	usd
CY2024Q2	tnxp	Grant Amount Awarded GrantAmountAwarded	34100000	usd
	us-gaap	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	0	usd
CY2024Q3	tnxp	Accrued Grant Income AccruedGrantIncome	1200000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6663378	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	262041	shares
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3346000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3611000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1953000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2539000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2632000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7489000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	7931000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	13639000	usd
CY2024Q3	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	1629000	usd
CY2023Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	4590000	usd
CY2024Q3	us-gaap	Grants Receivable Current GrantsReceivableCurrent	1595000	usd
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	199000	usd
CY2024Q3	tnxp	At The Market Receivable AtTheMarketReceivable	1680000	usd
CY2024Q3	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	2135000	usd
CY2024Q3	us-gaap	Prepaid Interest PrepaidInterest	523000	usd
CY2023Q4	us-gaap	Prepaid Interest PrepaidInterest	1513000	usd
CY2024Q3	us-gaap	Supplies Supplies	339000	usd
CY2023Q4	us-gaap	Supplies Supplies	508000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	340000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	143000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2125000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2228000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10366000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9181000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46347000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	99390000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3600000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5362000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42747000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94028000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	48800000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	965000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	965000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	965000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10100000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10100000	usd
CY2024Q3	tnxp	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	9147000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	953000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	477000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9623000	usd
CY2024Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9743000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	476000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	238000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	9355000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	11000000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2820000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2350000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	6535000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8650000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1363000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2089000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5172000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6561000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	705000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2820000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5830000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	9355000	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-32
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95543805	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2985924	shares
CY2024Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	245205	shares
CY2024Q2	tnxp	Minimum Bid Requirement Per Share MinimumBidRequirementPerShare	1.00
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q3	tnxp	Minimum Bid Requirement Per Share MinimumBidRequirementPerShare	1
CY2024Q3	tnxp	Period To Regain Compiance With Minimum Bid Requirement PeriodToRegainCompianceWithMinimumBidRequirement	P180D
CY2024Q3	tnxp	Period To Regain Compiance With Minimum Bid Requirement PeriodToRegainCompianceWithMinimumBidRequirement	P180D
CY2024Q3	tnxp	Additional Period To Regain Compiance With Minimum Bid Requirement AdditionalPeriodToRegainCompianceWithMinimumBidRequirement	P180D
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2822000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3989000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7512000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3989000	usd
CY2024Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4800000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	9200000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	43235	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	50542.10
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	338934	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	25996	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	34586.33
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	356173	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3622.40
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M25D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	65691	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17687.56
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y8M4D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.68
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26.88
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	127.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0358	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0533	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0342	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0435	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1189	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.4042	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2219	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.4272	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6307205	shares
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	75000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	299000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	142000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	139000	usd
CY2024Q3	tnxp	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	108000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	763000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	63000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	700000	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	222000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	434000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M3D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0481	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0463	pure
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
tnxp-20240930_cal.xml	Edgar Link	unprocessable
0001999371-24-014569-index-headers.html	Edgar Link	pending
0001999371-24-014569-index.html	Edgar Link	pending
0001999371-24-014569.txt	Edgar Link	pending
0001999371-24-014569-xbrl.zip	Edgar Link	pending
ex31-01.htm	Edgar Link	pending
ex31-02.htm	Edgar Link	pending
ex32-01.htm	Edgar Link	pending
ex32-02.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tnxp-10q_093024.htm	Edgar Link	pending
tnxp-20240930.xsd	Edgar Link	pending
tnxp-20240930_def.xml	Edgar Link	unprocessable
tnxp-20240930_lab.xml	Edgar Link	unprocessable
tnxp-20240930_pre.xml	Edgar Link	unprocessable
tnxp-10q_093024_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2024 Q4 Form 10-Q Financial Statement

#000199937124014569 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2024 Q4 Form 10-Q Financial Statement

#000199937124014569 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp